Liposome Technology Inc. announced Wednesday that it hasbegun a Phase III study in an AIDS patient with Kaposi'ssarcoma.
The clinical trial began Jan. 25 with Doxil, LTI's (NASDAQ:LTIZ)proprietary liposome formulation of doxorubicin, the mostwidely used cancer chemotherapy drug in the U.S. Doxil isbeing developed primarily for intravenous use in a variety ofmetastasizing tumors.
Kaposi's sarcoma affects approximately 20,000 AIDS patients ayear in the U.S.
The Menlo Park, Calif., company on Jan. 22 received permissionfrom the United Kingdom's Medicines Control Agency to beginthe Phase III study.
(c) 1997 American Health Consultants. All rights reserved.